These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
190 related articles for article (PubMed ID: 29853661)
1. Gemcitabine resistance mediated by ribonucleotide reductase M2 in lung squamous cell carcinoma is reversed by GW8510 through autophagy induction. Chen P; Wu JN; Shu Y; Jiang HG; Zhao XH; Qian H; Chen K; Lan T; Chen CG; Li J Clin Sci (Lond); 2018 Jul; 132(13):1417-1433. PubMed ID: 29853661 [TBL] [Abstract][Full Text] [Related]
2. Acquired tamoxifen resistance is surmounted by GW8510 through ribonucleotide reductase M2 downregulation-mediated autophagy induction. Li ZN; Shu Y; Chen CG; Li XQ; Li MY; Zhao XH; Wang S; Li J Biochem Biophys Res Commun; 2020 Jul; 528(3):554-560. PubMed ID: 32505349 [TBL] [Abstract][Full Text] [Related]
3. Synergistic Interactions between GW8510 and Gemcitabine in an In Vitro Model of Pancreatic Cancer. Rüstem DG; Atay S; Aydin HH; Ak H Anticancer Agents Med Chem; 2021 Oct; 21(16):2204-2215. PubMed ID: 33397269 [TBL] [Abstract][Full Text] [Related]
4. HDM-2 inhibition suppresses expression of ribonucleotide reductase subunit M2, and synergistically enhances gemcitabine-induced cytotoxicity in mantle cell lymphoma. Jones RJ; Baladandayuthapani V; Neelapu S; Fayad LE; Romaguera JE; Wang M; Sharma R; Yang D; Orlowski RZ Blood; 2011 Oct; 118(15):4140-9. PubMed ID: 21844567 [TBL] [Abstract][Full Text] [Related]
5. An increase in the expression of ribonucleotide reductase large subunit 1 is associated with gemcitabine resistance in non-small cell lung cancer cell lines. Davidson JD; Ma L; Flagella M; Geeganage S; Gelbert LM; Slapak CA Cancer Res; 2004 Jun; 64(11):3761-6. PubMed ID: 15172981 [TBL] [Abstract][Full Text] [Related]
6. Gambogic acid sensitizes gemcitabine efficacy in pancreatic cancer by reducing the expression of ribonucleotide reductase subunit-M2 (RRM2). Xia G; Wang H; Song Z; Meng Q; Huang X; Huang X J Exp Clin Cancer Res; 2017 Aug; 36(1):107. PubMed ID: 28797284 [TBL] [Abstract][Full Text] [Related]
7. Ribonucleotide reductase M2 is a promising molecular target for the treatment of oral squamous cell carcinoma. Iwamoto K; Nakashiro K; Tanaka H; Tokuzen N; Hamakawa H Int J Oncol; 2015 May; 46(5):1971-7. PubMed ID: 25738429 [TBL] [Abstract][Full Text] [Related]
8. Targeting the Warburg effect with a novel glucose transporter inhibitor to overcome gemcitabine resistance in pancreatic cancer cells. Lai IL; Chou CC; Lai PT; Fang CS; Shirley LA; Yan R; Mo X; Bloomston M; Kulp SK; Bekaii-Saab T; Chen CS Carcinogenesis; 2014 Oct; 35(10):2203-13. PubMed ID: 24879635 [TBL] [Abstract][Full Text] [Related]
9. Vasohibin 2 reduces chemosensitivity to gemcitabine in pancreatic cancer cells via Jun proto-oncogene dependent transactivation of ribonucleotide reductase regulatory subunit M2. Tu M; Li H; Lv N; Xi C; Lu Z; Wei J; Chen J; Guo F; Jiang K; Song G; Gao W; Miao Y Mol Cancer; 2017 Mar; 16(1):66. PubMed ID: 28327155 [TBL] [Abstract][Full Text] [Related]
10. Autophagy induction causes a synthetic lethal sensitization to ribonucleotide reductase inhibition in breast cancer cells. Chen YR; Tsou B; Hu S; Ma H; Liu X; Yen Y; Ann DK Oncotarget; 2016 Jan; 7(2):1984-99. PubMed ID: 26675256 [TBL] [Abstract][Full Text] [Related]
11. RNA interference targeting the M2 subunit of ribonucleotide reductase enhances pancreatic adenocarcinoma chemosensitivity to gemcitabine. Duxbury MS; Ito H; Zinner MJ; Ashley SW; Whang EE Oncogene; 2004 Feb; 23(8):1539-48. PubMed ID: 14661056 [TBL] [Abstract][Full Text] [Related]
12. mTORC2 regulates ribonucleotide reductase to promote DNA replication and gemcitabine resistance in non-small cell lung cancer. Tian L; Chen C; Guo Y; Zhang F; Mi J; Feng Q; Lin S; Xi N; Tian J; Yu L; Chen Y; Cao M; Lai C; Fan J; Zhang Y; Chen G Neoplasia; 2021 Jul; 23(7):643-652. PubMed ID: 34126361 [TBL] [Abstract][Full Text] [Related]
13. Potent effect of adenoviral vector expressing short hairpin RNA targeting ribonucleotide reductase large subunit M1 on cell viability and chemotherapeutic sensitivity to gemcitabine in non-small cell lung cancer cells. Tokunaga Y; Liu D; Nakano J; Zhang X; Nii K; Go T; Huang CL; Yokomise H Eur J Cancer; 2015 Nov; 51(16):2480-9. PubMed ID: 26254808 [TBL] [Abstract][Full Text] [Related]
14. Functional Genomic Screen in Mesothelioma Reveals that Loss of Function of BRCA1-Associated Protein 1 Induces Chemoresistance to Ribonucleotide Reductase Inhibition. Okonska A; Bühler S; Rao V; Ronner M; Blijlevens M; van der Meulen-Muileman IH; de Menezes RX; Wipplinger M; Oehl K; Smit EF; Weder W; Stahel RA; Penengo L; van Beusechem VW; Felley-Bosco E Mol Cancer Ther; 2020 Feb; 19(2):552-563. PubMed ID: 31619462 [TBL] [Abstract][Full Text] [Related]
15. Differential processing of let-7a precursors influences RRM2 expression and chemosensitivity in pancreatic cancer: role of LIN-28 and SET oncoprotein. Bhutia YD; Hung SW; Krentz M; Patel D; Lovin D; Manoharan R; Thomson JM; Govindarajan R PLoS One; 2013; 8(1):e53436. PubMed ID: 23335963 [TBL] [Abstract][Full Text] [Related]
16. Gemcitabine-based chemogene therapy for pancreatic cancer using Ad-dCK::UMK GDEPT and TS/RR siRNA strategies. Réjiba S; Bigand C; Parmentier C; Hajri A Neoplasia; 2009 Jul; 11(7):637-50. PubMed ID: 19568409 [TBL] [Abstract][Full Text] [Related]
17. Inhibition of SRC tyrosine kinase impairs inherent and acquired gemcitabine resistance in human pancreatic adenocarcinoma cells. Duxbury MS; Ito H; Zinner MJ; Ashley SW; Whang EE Clin Cancer Res; 2004 Apr; 10(7):2307-18. PubMed ID: 15073106 [TBL] [Abstract][Full Text] [Related]
18. Sorafenib Inhibits Ribonucleotide Reductase Regulatory Subunit M2 (RRM2) in Hepatocellular Carcinoma Cells. Yang PM; Lin LS; Liu TP Biomolecules; 2020 Jan; 10(1):. PubMed ID: 31936661 [TBL] [Abstract][Full Text] [Related]
19. Expression of nucleoside transporters, deoxycitidine kinase, ribonucleotide reductase regulatory subunits, and gemcitabine catabolic enzymes in primary ovarian cancer. Ferrandina G; Mey V; Nannizzi S; Ricciardi S; Petrillo M; Ferlini C; Danesi R; Scambia G; Del Tacca M Cancer Chemother Pharmacol; 2010 Mar; 65(4):679-86. PubMed ID: 19639316 [TBL] [Abstract][Full Text] [Related]
20. Inhibition of ribonucleotide reductase subunit M2 enhances the radiosensitivity of metastatic pancreatic neuroendocrine tumor. Chow Z; Johnson J; Chauhan A; Jeong JC; Castle JT; Izumi T; Weiss H; Townsend CM; Schrader J; Anthony L; Yang ES; Evers BM; Rychahou P Cancer Lett; 2024 Aug; 596():216993. PubMed ID: 38801884 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]